Richard Dobbs

Boris’s Dunkirk moment

The Prime Minister can still get Britain’s Covid response back on track

issue 26 September 2020

It’s hard to deny that Boris Johnson’s government has so far had a ‘bad war’ against the pandemic. Our death toll is high compared with other countries and our economy is in worse shape. We face rising cases, increased hospital admissions and more restrictions. It’s all so bleak; yet that is why now is precisely the moment for Boris to imitate his great hero, Winston Churchill. In the coming months, Britain can play as pivotal a role in a global victory against the virus as we did in the second world war.

The war analogies only go so far, of course. We are fighting a virus, not an evil ideology. But there are similarities. Like the second world war, Covid has caused UK government debt to exceed GDP. Moreover, just as the air force, navy, and army — backed by British science and technology — delivered victory in the 1940s, we are now ready to unleash the three attack branches of treatment, mass-testing and vaccines to defeat the virus.

Treatment is the air force in our Covid war. We have learnt a lot in nine months and, as we gear up for another wave, we are likely to reduce the risk of death for those badly infected. We have seen the benefits of simple breathing interventions, such as moving patients on to their stomachs. Better still, Britain is leading the way in identifying and developing new treatment drugs.

‘I’m really worried we may be allowed to visit the in-laws.’

In March, we established the national clinical recovery trial to investigate a range of potential treatments. In June, this trial announced that the low-cost steroid dexamethasone reduces death by up to a third in patients with severe respiratory complications. It is still investigating the efficacy of azithromycin (a common antibiotic), tocilizumab (an anti-inflammatory treatment) and convalescent plasma (from Covid patients who have recovered).

GIF Image

Disagree with half of it, enjoy reading all of it

TRY 3 MONTHS FOR $5
Our magazine articles are for subscribers only. Start your 3-month trial today for just $5 and subscribe to more than one view

Comments

Join the debate for just $5 for 3 months

Be part of the conversation with other Spectator readers by getting your first three months for $5.

Already a subscriber? Log in